Jubilant Pharmova Limited
JPM is engaged in speciality pharmaceuticals, contract development and manufacturing, generics, drug discovery and proprietary novel drug businesses. It manufactures and supplies radiopharmaceuticals, with a network of 49 radio-pharmacies in the US, ...
Key Metrics
EPS
4.87
Current ratio
2.05
Debt/Equity
0.77
Debt/EBITDA
5.04
Interest coverage ratio
1.63
Operating Cashflow to total debt
0.23
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Cons
Stock is trading at 2.54 times its book value
The company has delivered a poor sales growth of -5.95% over past five years.
Company has a low return on equity of 0.55% over last 3 years.
Earnings include an other income of Rs.315 Cr.
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Jubilant Pharmova Limited bond.
This comprehensive profile covers key factual information about Jubilant Pharmova Limited. JPM is engaged in speciality pharmaceuticals, contract development and manufacturing, generics, drug discovery and proprietary novel drug businesses. It manufactures and supplies radiopharmaceuticals, with a network of 49 radio-pharmacies in the US, allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, APIs and solid dosage formulations through six USFDA-approved manufacturing facilities in the US, Canada and India. EPS in Mar-2024 was 4.87. Current ratio in Mar-2024 was 2.05. Debt/Equity in Mar-2024 was 0.77. Debt/EBITDA in Mar-2024 was 5.04. Interest coverage ratio in Mar-2024 was 1.63. Operating Cashflow to total debt in Mar-2024 was 0.23. Total revenue for Mar-2025(E) was ₹7,257.83. Net income for Mar-2025(E) stood at ₹119.24. Total assets as of Mar-2024 were ₹11,337.70. Operating cash flow for Mar-2024 was ₹971.30. Peers and comparison entities consist of Jubilant Pharmova Limited, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr Reddy's Laboratories Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: ; ; ; . Key risks include: Stock is trading at 2.54 times its book value; The company has delivered a poor sales growth of -5.95% over past five years.; Company has a low return on equity of 0.55% over last 3 years.; Earnings include an other income of Rs.315 Cr.. Leadership team details include Shyam S Bhartia (Chairman & Managing Director), Pramod Yadav (Director & Chief Executive Officer), Chris Preti (CEO - CDMO), Sergio Calvo (Senior Vice Precedent and Head, Radiopharmaceuticals Business), Kevin Fortier (Chief Commercial Officer, US Generics Business), Jasdeep Singh Sood (Senior Vice Precedent and Head, Non-US Generics Business), Dr. Indranil Nandi (Senior Vice Precedent and Head, R&D), Mitch Guss (Vice Precedent and Head, Legal). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.